Sarah Cannon Names New CFO

Friday, March 19, 2010 07:05 AM

Strategic research organization Sarah Cannon Research Institute (SCRI) appointed Dean Ferrigno as chief financial officer (CFO), replacing Phil Cestaro, who is now president, SCRI Services. SCRI Services specializes in clinical trial administration with a focus on oncology drug development programs. Cestaro, who joined the company in 2006, will continue to be SCRI’s chief information officer in addition to the new position.

More... »

WIRB Copernicus Group

CenterWatch Monthly May 2009

Friday, May 1, 2009 11:00 AM

U.S. Sites Rate Novo Nordisk, Novartis and Eisai as Top Sponsors in 2009

More... »

CRF Health eCOA webinar series

JLL Partners Completes Acquisition of PharmaNet

Tuesday, March 31, 2009 09:36 AM

Contract research organization (CRO) PharmaNet is officially a private company after private equity firm JLL Partners completed its acquisition of the CRO yesterday.

More... »

JLL Partners Extends Deadline for Tender Offer of PharmaNet Shares

Friday, March 13, 2009 12:00 PM

PharmaNet Development Group stockholders have another week to tender their shares as part of the contract research organization (CRO)’s pending acquisition by private equity firm JLL Partners.

More... »

PharmaNet Launches Clinical Trial Staffing Service

Thursday, March 12, 2009 09:00 AM

Despite a pending acquisition by private equity firm JLL Partners, contract research organization (CRO) PharmaNet continues to expand its service offerings and locations.

More... »

PharmaNet Earnings Plummet in Q4

Thursday, February 26, 2009 11:23 AM

In what could be PharmaNet Development Group’s last earnings release as a public company, the contract research organization (CRO) reported its 2008 financial information late last night without an investor conference call.

More... »

PharmaNet to Open Brazil Office

Thursday, February 19, 2009 09:00 AM

PharmaNet Development Group is expanding its presence in Latin America with the opening of a new office in Sao Paulo, Brazil.

More... »

PharmaNet to Go Private in $250M Deal

Tuesday, February 3, 2009 10:04 AM

PharmaNet Development Group signed a definitive merger agreement with private equity firm JLL Partners, a deal that will make the now public contract research organization (CRO) a private company.

More... »

PharmaNet Pursues Strategic Alternatives, Possible Sale

Friday, December 19, 2008 11:57 AM

Troubled contract research organization (CRO) PharmaNet Development Group announced Thursday that it is working with a financial advisor from USB Investment Bank to explore strategic alternatives, including the potential sale of the company.

More... »

PharmaNet Revenues Drop

Thursday, October 30, 2008 10:43 AM

PharmaNet Development is the latest contract research organization (CRO) to release disappointing quarterly earnings as a result of contract cancellations, slow sales and negative foreign exchange rates. Princeton, N.J.-based PharmaNet reported a decrease in direct revenue to $89.2 million, down $10 million, or 10.6%, from the same period last year. Almost $1.5 million of that drop was a result of foreign currency exchange translation.

More... »

CenterWatch Data Library



Browse by:


July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs